Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0593 • ACR Convergence 2022
A New Cytokine Interleukin 40 Is Elevated in the Serum of Patients with Early Rheumatoid Arthritis and Associates with Autoantibodies and Neutrophil Activation
Adéla Navrátilová¹, Viktor Bečvář¹, Hana Hulejová¹, Michal Tomcik², Heřman Mann², Olga Růžičková¹, Olga Šléglová³, Jakub Závada¹, Karel Pavelka⁴, Jiří Vencovský⁵, Ladislav Šenolt⁵ and Lucie Andrés Cerezo¹, ¹Institute of Rheumatology, Prague, Czech Republic, ²Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ³Institute of Rheumatology, Prague, ⁴Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha, Czech Republic, ⁵Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: IL-40 is a newly described cytokine related to malignant transformation and immune system function. In our previous study, we showed that IL-40 is elevated…
Abstract Number: 0610 • ACR Convergence 2022
Patient-derived Organoids Reveal Transcriptional Regulation of Synovial Lining Fibroblast Differentiation
Sonia Presti¹, Gerald FM Watts¹, Zhu Zhu¹, Kartik Bhamidipati¹, Junning Case¹, Yuhong Li¹, Teri Bowman¹, Suppawat Kongthong¹, ilya Korsunsky¹, Michael Brenner² and Kevin Wei³, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Synovial lining fibroblasts secrete factors into the joint cavity that promote joint lubrication1. In inflammatory arthritis, sublining fibroblasts undergo marked expansion while lining fibroblasts…
Abstract Number: 0627 • ACR Convergence 2022
Spatial Transcriptomic Analysis Reveals Vascular Zonation of Myofibroblasts in Rheumatoid Arthritis Synovium
Kartik Bhamidipati¹, Roopa Madhu¹, Sonia Presti¹, Youngmi Kim², Ye Cui², Fan Zhang³, Anna Jonsson¹, Aparna Nathan¹, Nghia Millard¹, Deepak Rao¹, Laura Donlin⁴, Jennifer Anolik⁵, Soumya Raychaudhuri¹, Michael Brenner⁶, Ilya Korsunsky¹ and Kevin Wei⁷, ¹Brigham and Women's Hospital, Boston, MA, ²Nanostring Technologies Inc., Seattle, WA, ³University of Colorado, Aurora, CO, ⁴Hospital for Special Surgery, New York, NY, ⁵University of Rochester Medical Center, Rochester, NY, ⁶Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Many rheumatoid arthritis (RA) patients do not achieve sustained remission despite multiple lines of therapy. Recent studies have linked the expansion of synovial fibroblasts…
Abstract Number: 0762 • ACR Convergence 2022
Rituximab-treated Rheumatic Patients: B-cell Levels Predict Sero-conversion After COVID-19 Boost or Re-vaccination in Initial Vaccine Non-responders
Christian Ammitzboell¹, marianne Kragh thomsen², Jakob Bøgn Andersen¹, Jens Magnus Berth Jensen³, marie-Louise From Hermansen¹, anders Dahl Johannsen¹, Mads Lamm Larsen¹, Clara Elbæl Mistegaard¹, Susan Mikkelsen³, Fruzsina Szabados³, Signe Risbøl Vils¹, Christian Erikstrup³, Ellen-Margrethe Hauge¹ and Anne Troldborg¹, ¹Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ²Department of Clinical Microbiology, Aarhus University Hospital, Aarhus, Denmark, ³Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Treatment with rituximab (RTX) has presented a challenge during the COVID-19 pandemic, as antibody response after primary vaccination are markedly reduced and often undetectable.The primary…
Abstract Number: 0883 • ACR Convergence 2022
Serum Cholesterol Loading Capacity on Macrophages Is Dependent on Oxidized Low-density Lipoprotein and Regulated by Seropositivity and C-reactive Protein in Patients with Rheumatoid Arthritis
George A Karpouzas¹, Bianca Papotti², Sarah Ormseth³, Marcella Palumbo², elizabeth Hernandez³, Maria Pia Adorni², Francesca Zimetti², Matthew Budoff⁴ and Nicoletta Ronda⁵, ¹Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ²University of Parma, Parma, Italy, ³The Lundquist Institute, Torrance, CA, ⁴Harbor-UCLA Medical Center and the Lundquist Institute, Torrance, CA, ⁵University of Parma, Parma
Background/Purpose: Excessive cholesterol accumulation in macrophages underlies foam cell formation, initiation and progression of atherosclerosis. Low-density lipoprotein (LDL) oxidation and unregulated uptake by macrophages are…
Abstract Number: 0900 • ACR Convergence 2022
Effect of Biologic Agents on Lipid Levels and Cardiovascular Risk in Rheumatoid Arthritis Patients
Dimitrios Pappas¹, Jon Giles², George Reed³, Kevin Kane⁴, Jeffrey Curtis⁵ and Joel Kremer⁶, ¹CorEvitas, LLC, Waltham, MA, ²Columbia University, New York, NY, ³The Corrona Research Foundation and University of Massachusetts, Albany, NY, ⁴University of Massachusetts, Worcester, MA, ⁵University of Alabama at Birmingham, Hoover, AL, ⁶The Corrona Research Foundation, Delray Beach, FL
Background/Purpose: Cardiovascular (CV) risk in RA is increased due to interaction between traditional risk factors and systemic inflammation. The purpose of this analysis was to…
Abstract Number: 0916 • ACR Convergence 2022
Should RA Patients with Controlled Disease Taper Methotrexate from Targeted Therapy or Continue It? Risk Differences in Sustaining Remission from a Systematic Review and Meta-analysis
Charis Meng, Diviya Rajesh, Bridget Jivanelli, Deanna Jannat-Khah, DrPH, MSPH and Vivian Bykerk, Hospital for Special Surgery, New York, NY
Background/Purpose: Patients with RA often struggle with side effects of methotrexate (MTX). ACR guidelines conditionally recommend the tapering of MTX before tapering biologic (b)DMARDs, but…
Abstract Number: 0933 • ACR Convergence 2022
Exploratory Study of the Usefulness of TNFAIP3 Genetic Variants in Predicting Response to Methotrexate in Early Arthritis Patients
Ana Triguero¹, JUAN BALDIVIESO ACHA², Emilia Roy Vallejo³, Patricia Quiroga-Colina⁴, Irene Maria Llorente Cubas², Rosario Garcia-Vicuña⁵, amaya Puig kröger⁶ and Isidoro Gonzalez², ¹Hospital Universitario La Princesa, Madrid, Spain, ²Hospital Universitario de La Princesa, Madrid, Spain, ³Internal Medicine Department, Hospital Universitario La Princesa, Instituto de Investigación Sanitaria La Princesa (IIS-IP), Madrid, Spain, ⁴Division of Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, ⁵Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ⁶Laboratory of Immunometabolism, Hospital General Universitario Gregorio Marañón, Madrid, Spain
Background/Purpose: We recently described that methotrexate (MTX) could exert its immunomodulatory effect through the induction of A20 expression , a protein that negatively regulates NFkB…
Abstract Number: 1130 • ACR Convergence 2022
Identification of Novel Molecular Signatures Associated with the Therapeutic Response to DMARDs and TNFi Therapies in Rheumatoid Arthritis Patients Through High Throughput Proteomics
Carlos Pérez-Sánchez¹, Laura Muñoz-Barrera¹, Tomás Cerdó², Ismael Sánchez-Pareja², Jerusalem Calvo-Gutierrez², Rafaela Ortega-Castro¹, Montserrat Romero-Gomez², María Ángeles Aguirre-Zamorano³, María Carmen Ábalos-Aguilera⁴, Nuria Barbarroja¹, José Perez-Venegas⁵, Mª Dolores Ruiz-Montesinos⁵, Carmen Dominguez⁵, Carlos Rodriguez-Escalera⁶, Carmen Romero-Barco⁶, Antonio Fernandez-Nebro⁷, Natalia Mena Vazquez⁷, Jose Luis Marenco⁸, Julia Uceda Montañez⁸, Charo Santos⁹, Eduardo Collantes¹, Alejandro Escudero-Contreras² and Chary Lopez-Pedrera¹, ¹IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, ²IMIBIC/University of Cordoba/Reina Sofia Hospital, Córdoba, Spain, ³Reina Sofía University Hospital/ Rheumatology Department, Córdoba, Spain, ⁴Imibic/ University of Córdoba/ Reina Sofía Hospital, Córdoba, Spain, ⁵Virgen Macarena University Hospital, Sevilla, Spain, ⁶Virgen de la Victoria Hospital, Málaga, Spain, ⁷Regional University Hospital of Málaga, Málaga, Spain, ⁸Virgen de Valme University Hospital, Sevilla, Spain, ⁹Virgen de Valme University Hospital, Málaga, Spain
Background/Purpose: The clinical outcome of conventional disease-modifying antirheumatic drugs (DMARDs) and TNF inhibitors (TNFi) is still unpredictable in rheumatoid arthritis (RA) patients. Thus, innovative analyses…
Abstract Number: 1241 • ACR Convergence 2022
Towards a Simplified Fluid-sensitive MRI Protocol in Small Joints of the Hand in Early Arthritis Patients: Reliability Between mDixon and Regular FSE Fat Saturation MRI-sequences
Anna M.P. Boeren¹, Ellis Niemantsverdriet², Marloes Verstappen³, Fenne Wouters⁴, Monique Reijnierse³, J.L. Bloem⁵ and Annette van der Helm-van Mil⁶, ¹Erasmus MC, Rotterdam, Rotterdam, ²LUMC, Leiden, Netherlands, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Leiden University Medical Centre (LUMC), Leiden, ⁵Leiden University Medical Centre (LUMC), Leiden, Netherlands, ⁶Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands
Background/Purpose: MRI of small joints is, despite its sensitivity in demonstrating inflammation, hardly used in rheumatologic clinical practice. Widespread use is hampered by invasiveness, long…
Abstract Number: 1353 • ACR Convergence 2022
Dietary Practices and Beliefs of Patients with Rheumatic Diseases and Relationship with Symptoms: Results of a Multicenter Cross-sectional Study
Domitille RENARD¹, Sophie Tuffet², Philippe Dieude³, Pascal Claudepierre⁴, Laure Gossec⁵, Bruno Fautrel⁶, Anna Molto⁷, Corinne MIceli⁸, Pascal Richette⁹, Emmanuel Maheu¹⁰, Claire Carette¹¹, Sebastien Czernichow¹¹, Chloe JAMAKORZYAN¹², alexandra Rousseau², Francis Berenbaum¹³, Catherine Beauvais¹⁴ and Jérémie SELLAM¹⁵, ¹Sorbonne University Paris- Sant Antoine Hospital, Paris, France, ²Saint Antoine hospital, Paris, Ile-de-France, France, ³Université Paris Cité, Paris, France, ⁴Paris Est Creteil University, Creteil, France, ⁵Sorbonne Université, Paris, France, ⁶Sorbonne University Paris, France and Pierre Louis Institute of Epidemiology and Public Health, Paris, France, Paris, France, ⁷Rheumatology Department, Cochin Hospital, APHP, Paris, France, ⁸APHP, Paris, France, ⁹Department of Rheumatology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France, ¹⁰Hôpital Paris Saint Antoine, Moirans, Auvergne-Rhône-Alpes, France, ¹¹Hôpital Européen Georges Pompidou, Paris, France, ¹²Hopital Begin, Saint-Mandé, France, ¹³Sorbonne University - Saint-Antoine hospital, Paris, France, ¹⁴Saint Antoine hospital, Paris, France, ¹⁵Sorbonne Universite, AP-HP, Saint-Antoine hospital, Paris, France
Background/Purpose: Diet is a subject of questioning and beliefs among patients with rheumatic diseases. They are inclined to change their eating habits and sometimes follow…
Abstract Number: 1400 • ACR Convergence 2022
Machine Learning Identifies Molecular Phenotypes That Predict Incident Cardiovascular Disease in Patients with Rheumatoid Arthritis
Tate Johnson¹, Rebekah Gundry², Merry Lindsey², Punyasha Roul³, Yangyuna Yang², Joshua Baker⁴, Brian Sauer⁵, Grant Cannon⁶, Geoffrey Thiele², Ted Mikuls⁷ and Bryant England², ¹University of Nebraska Medical Center, Elkhorn, NE, ²University of Nebraska Medical Center, Omaha, NE, ³UNMC, Omaha, NE, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶Retired, Salt Lake City, UT, ⁷Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Cardiovascular disease (CVD) remains the leading cause of death in patients with rheumatoid arthritis (RA). General population CVD risk calculators underestimate risk in RA,…
Abstract Number: 1416 • ACR Convergence 2022
Bioactive Lipid Profiling Can Identify Dynamic Biomarkers in Response to Biologic Therapy Result of the CorEvitas CERTAIN Comparative Effectiveness Study
Roxana Coras¹, Mona Alotaibi², Dimitrios Pappas³, Joel Kremer⁴, Jeffrey Curtis⁵, Arthur Kavanaugh⁶, Ted Mikuls⁷, Geoffrey Thiele⁸, mohit jain² and Monica Guma⁹, ¹University of California San Diego, San Diego, CA, ²Department of Medicine, School of Medicine, University of California San Diego, San Diego, CA, ³CorEvitas, LLC, Waltham, MA, ⁴The Corrona Research Foundation, Delray Beach, FL, ⁵University of Alabama at Birmingham, Hoover, AL, ⁶University of California San Diego, La Jolla, CA, ⁷Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁸University of Nebraska Medical Center, Omaha, NE, ⁹UCSD, La Jolla, CA
Background/Purpose: Bioactive lipids comprise distinct classes of bioactive molecules with functions that are critical for joint disease, including regulation of not only inflammation but also…
Abstract Number: 1436 • ACR Convergence 2022
Predictors at Diagnosis for Start of Biologic Disease Modifying Anti-Rheumatic Drugs in Patients with Early Rheumatoid Arthritis
Mohaned Hameed¹, Sofia Exarchou¹, Anna Eberhard¹, Ankita Sharma¹, Ulf Bergström¹, Jon Einarsson² and Carl Turesson³, ¹Lund University, Malmö, Sweden, ²Skåne University Hospital, Lund, Sweden, ³Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden
Background/Purpose: With increasing use of biologic disease modifying anti-rheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) for the management of rheumatoid arthritis (RA), outcomes have…
Abstract Number: 1630 • ACR Convergence 2022
Single-cell Profiling of B Cell Repertoire and Gene Expression in the RA Synovium Reveals Tissue Specific Clonal Expansion
Aaron Wagner¹, Nida Meednu², Garrett Dunlap³, Fan Zhang⁴, Anna Jonsson⁵, Kevin Wei⁶, Ami Ben-artzi⁷, Lindsy Forbess⁸, Laura Geraldino-Pardilla⁹, Diane Horowitz¹⁰, Laura Hughes¹¹, Arthur Mandelin¹², Karen Salomon-Escoto¹³, Darren Tabechian¹⁴, Edward DiCarlo¹⁵, Ellen Gravallese¹⁶, Brendan Boyce¹⁷, Christopher Ritchlin¹⁸, James Lederer⁵, Mandy McGeachy¹⁹, Peter Gregersen²⁰, Paul Utz²¹, William Robinson²¹, Holden Maecker²¹, Judith James²², Joel Guthridge²², Harris Perlman²³, Joan Bathon⁹, Susan Goodman¹⁵, Gary S. Firestein²⁴, David Boyle²⁵, S. Louis Bridges, Jr.¹⁵, Kevin D Deane²⁶, V. Michael Holers²⁷, Larry Moreland²⁷, Andrew Filer²⁸, Costantino Pitzalis²⁹, Vivian Bykerk¹⁵, Laura Donlin¹⁵, Soumya Raychaudhuri⁵, Michael Brenner¹⁶, AMP RA/Lupus¹⁷, Deepak Rao⁵, Andrew McDavid¹ and Jennifer Anolik², ¹University of Rochester, Rochester, NY, ²University of Rochester Medical center, Rochester, NY, ³Harvard University, Boston, MA, ⁴University of Colorado, Aurora, CO, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁷Ami Ben-Artzi, MD Inc., Beverly Hills, CA, ⁸Cedars-Sinai Medical Center, Los Angeles, CA, ⁹Columbia University, New York, NY, ¹⁰Northwell Health, Jericho, NY, ¹¹University of Alabama at Birmingham, Birmingham, AL, ¹²Northwestern University Feinberg School of Medicine, Chicago, IL, ¹³University of Massachusetts Medical School, Worcester, MA, ¹⁴URMC, Rochester, NY, ¹⁵Hospital for Special Surgery, New York, NY, ¹⁶Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ¹⁷University of Rochester, Rochester, ¹⁸Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ¹⁹University of Pittsburgh, Pittsburgh, PA, ²⁰The Feinstein Inst for Med Research, Larchmont, NY, ²¹Stanford University School of Medicine, Palo Alto, CA, ²²Oklahoma Medical Research Foundation, Oklahoma City, OK, ²³Northwestern University, Chicago, IL, ²⁴University of California, San Diego, San Diego, CA, ²⁵UCSD, La Jolla, CA, ²⁶University of Colorado Denver Anschutz Medical Campus, Denver, CO, ²⁷University of Colorado, Denver, CO, ²⁸University of Birmingham, Birmingham, United Kingdom, ²⁹Queen Mary University of London, London, United Kingdom
Background/Purpose: Ectopic lymphoid structures can develop in rheumatoid arthritis (RA) synovial tissue, but the precise pathways of B cell activation and selection are not well…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].